Introduction: Proton beam therapy (PBT) is an effective treatment option for uveal melanomas. Following treatment, it may take many months for the tumour to respond and it may initially enlarge. We reviewed our PBT patients to determine when they showed a radiological response to treatment. Methods: Patients undergoing PBT for ciliary body or choroidal melanomas between 2008 and 2018 were included. Data were collected on patient demographics, treatments before and after PBT and survival. All ultrasound investigations prior and since PBT were reviewed and tumour volume calculated using a validated formula for a half-ellipsoid shape. Results: 193 patients were analysed, 169 with choroidal and 24 with ciliary body melanomas. 31.6% patients had other treatment prior to PBT. At a mean of 8 months post-PBT, 64.7% of patients had a reduced tumour volume with 20.2% having larger tumours. At a mean of 15 months post-treatment, these figures were 67.8% and 10.3%. 18.1% of patients had an enucleation during the study period. The earliest responses were seen at 2 months, the latest at 32 months post-treatment. 5-year melanoma-specific survival was 82.3%. Conclusions: In our study, by 6 months post-PBT, a majority of patients show a reduction in tumour volume. Of those that do not, many respond in the next 6 months and a response may be seen up to 32 months after treatment. Patients may need to be monitored for up to 32 months to see a final response to PBT treatment.

Journal Section:
Research Article
Keywords:
Uveal melanoma, Proton beam therapy, Radiological response
1.
Jager M, Shields C, Cebulla C. Uveal melanoma. Nat Rev Dis Primers. 2020 9;6(1):24.
https://doi.org/10.1038/s41572-020-0158-0
2.
Dogrusöz M, Jager M, Damato B. Uveal melanoma treatment and prognostication. Asia Pac J Ophthalmol. 2017;6(2):186–96.
https://doi.org/10.22608/APO.201734
3.
Jamison A, Bhatti L, Sobti M, Chadha V, Cauchi P, Kemp E. Uveal melanoma-associated survival in Scotland. Eye. 2019;33(11):1699–706.
https://doi.org/10.1038/s41433-019-0622-9
4.
Sabazade S, Herrspiegel C, Gill V, Stålhammar G. No differences in the long-term prognosis of iris and choroidal melanomas when adjusting for tumor thickness and diameter. BMC Cancer. 2021 24;21(1):1270.
https://doi.org/10.1186/s12885-021-09002-0
5.
Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006;124(12):1684–93.
https://doi.org/10.1001/archopht.124.12.1684
6.
Damato B, Kacperek A, Errington D, Heimann H. Proton beam radiotherapy of uveal melanoma. Saudi J Ophthalmol. 2013;27(3):151–7.
https://doi.org/10.1016/j.sjopt.2013.06.014
7.
Reichstein D, Brock A. Radiation therapy for uveal melanoma: a review of treatment methods available in 2021. Curr Opin Ophthalmol. 2021;32(3):183–90.
https://doi.org/10.1097/ICU.0000000000000761
8.
Tsang DS, Patel S. Proton beam therapy for cancer. CMAJ. 2019 17;191(24):E664–6.
https://doi.org/10.1503/cmaj.190008
9.
Groenewald C, Konstantinidis L, Damato B. Effects of radiotherapy on uveal melanomas and adjacent tissues. Eye. 2013;27(2):163–71.
https://doi.org/10.1038/eye.2012.249
10.
Damato B, Kacperek A, Chopra M, Campbell I, Errington R. Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience. Int J Radiat Oncol Biol Phys. 2005;62(5):1405–11.
https://doi.org/10.1016/j.ijrobp.2005.01.016
11.
Papakostas TD, Lane AM, Morrison M, Gragoudas ES, Kim IK. Long-term outcomes after proton beam irradiation in patients with large choroidal melanomas. JAMA Ophthalmol. 2017;135(11):1191–6.
https://doi.org/10.1001/jamaophthalmol.2017.3805
12.
Macdonald ECA, Cauchi P, Kemp EG. Proton beam therapy for the treatment of uveal melanoma in Scotland. Br J Ophthalmol. 2011;95(12):1691–5.
https://doi.org/10.1136/bjo.2010.195594
13.
Wilkes SR, Gragoudas ES. Regression patterns of uveal melanomas after proton beam irradiation. Ophthalmology. 1982;89(7):840–4.
https://doi.org/10.1016/s0161-6420(82)34731-4
14.
Richtig E, Langmann G, Mullner K, Richtig G, Smolle J. Calculated tumour volume as a prognostic parameter for survival in choroidal melanomas. Eye. 2004;18(6):619–23.
https://doi.org/10.1038/sj.eye.6700720
15.
Foti PV, Farina R, Coronella M, palmucci S, Montana A, Sigona A, et al. Diffusion-weighted magnetic resonance imaging for predicting and detecting the response of ocular melanoma to proton beam therapy: initial results. Radiol Med. 2015;120(6):526–35.
https://doi.org/10.1007/s11547-014-0488-7
16.
Kim TW, Choi E, Park J, Shin DH, Jung S, Seok S, et al. Clinical outcomes of proton beam therapy for choroidal melanoma at a single Institute in korea. Cancer Res Treat. 2018;50(2):335–44.
https://doi.org/10.4143/crt.2017.070
17.
Mishra KK, Daftari IK. Proton therapy for the management of uveal melanoma and other ocular tumors. Chin Clin Oncol. 2016;5(4):50.
https://doi.org/10.21037/cco.2016.07.06
18.
Riechardt AI, Cordini D, Dobner B, Seibel I, Gundlach E, Rehak M, et al. Salvage proton beam therapy in local recurrent uveal melanoma. Am J Ophthalmol. 2014 Nov;158(5):948–56.
https://doi.org/10.1016/j.ajo.2014.07.013
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.